Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cerebellar-Targeted Repetitive Transcranial Magnetic Stimulation (rTMS) for Autism Spectrum Disorder: A Novel Treatment Approach

NCT07910305 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.

NCT NCT07910305 Not yet recruiting Not applicable 120 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07910305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, 120 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital; China. Primary measure: Change in Social Responsiveness Scale (SRS) Total Score From Baseline to Week 2.

How it compares

1,092 similar trials: same condition (Autism Spectrum Disorder) and phase

Enrollment

This trial
120
Middle half
29 to 100
Median
52
Trials with a value
1,092

Months from start to completion

This trial
26
Middle half
12.2 to 42
Median
24
Trials with a value
1,090

Sites

This trial
1
Middle half
1 to 1
Median
1
Trials with a value
1,015
Posted results or a linked paper 44% 482 of 1,092 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Cerebellar-Targeted Repetitive Transcranial Magnetic Stimulation (rTMS) for Autism Spectrum Disorder: A Novel Treatment Approach
Lead sponsor
Sir Run Run Shaw Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2028
Enrollment
120 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Autism Spectrum Disorder

Registry terms: tms

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
6 Years
Maximum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Sir Run Run Shaw Hospital

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
Individualized Cerebellar-Targeted rTMS Experimental Individualized Cerebellar-Targeted Repetitive Transcranial Magnetic Stimulation
Show registry wording

Participants in this arm will receive individualized cerebellar-targeted repetitive transcranial magnetic stimulation (rTMS) guided by MRI-based neuronavigation. The stimulation will be delivered using an intermittent theta-burst stimulation (iTBS) protocol at 90% of the resting motor threshold (RMT). Each treatment day will consist of two stimulation sessions separated by a 15-minute rest interval, delivering a total of 1,200 pulses per day. Treatment will be administered five days per week for two consecutive weeks, resulting in a total of 10 treatment days. Clinical assessments and MRI examinations will be performed at baseline, week 2, and week 12 to evaluate treatment-related changes in ASD symptoms and brain function.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Change in Social Responsiveness Scale (SRS) Total Score From Baseline to Week 2 Baseline and Week 2
Show registry wording

The Social Responsiveness Scale (SRS) is a caregiver-reported questionnaire used to assess social communication and interaction difficulties in individuals with autism spectrum disorder. The scale consists of 65 items, each rated from 0 to 3, with a total score ranging from 0 to 195. Higher scores indicate greater severity of social impairment. The primary outcome is the change in SRS total score from baseline to week 2 following individualized cerebellar-targeted repetitive transcranial magnetic stimulation (rTMS).

Lead sponsor's other trials

Sir Run Run Shaw Hospital, most recent start first.

Similar trials

Same condition (Autism Spectrum Disorder) and phase, most recent start first.